drugset
drugset / Trial / NCT04481815

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT04481815 ↗

Phase 2 Unknown 240 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedParallel-groupOpen-labelTreatment

Summary

It is a multicenter, open-Label, randomised phase 2 study to compare the efficacy and safety study of R2-MTX chemotherapy（Lenalidomide, Rituximab and Methotrexate）with R-MTX chemotherapy（Rituximab and Methotrexate ）as first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma.2-year Progression free survival (PFS) is the primary endpoint.

Timeline

Start
2020-10-01
Primary completion
2023-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Methotrexate Small molecule 3.5 g Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

primary central nervous system lymphoma